The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

The following sympathomimetic amine has agonistic
action on α1 + α2 + β1 + β3 adrenoceptors, but not on
β2 receptors:
A. Adrenaline
B. Noradrenaline
C. Isoprenaline
D. Phenylephrine
by

1 Answer

Answer :

B. Noradrenaline
by

Related questions

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Last Answer : Ans: D

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Description : The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Last Answer : B. Dilatation of pupil

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Description : The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location

Which of the following is a noncatecholamine sympathomimetic: A. Adrenaline B. Ephedrine C. Dopamine D. Isoprenaline

Description : Which of the following is a noncatecholamine sympathomimetic: A. Adrenaline B. Ephedrine C. Dopamine D. Isoprenaline

Last Answer : B. Ephedrine

Which of the following is a noncatecholamine sympathomimetic: A. Adrenaline B. Ephedrine C. Dopamine D. Isoprenaline

Description : Which of the following is a noncatecholamine sympathomimetic: A. Adrenaline B. Ephedrine C. Dopamine D. Isoprenaline

Last Answer : B. Ephedrine

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

The following are true: a. heroin causes miosis by increasing the release of acetylcholine. b. botulinum toxin causes mydriasis by inhibiting the release of acetylcholine c. phenylephrine causes mydriasis by stimulating the alpha receptors d. amphetamine causes mydriasis by inhibiting noradrenaline reuptake

Description : The following are true: a. heroin causes miosis by increasing the release of acetylcholine. b. botulinum toxin causes mydriasis by inhibiting the release of acetylcholine c. ... mydriasis by stimulating the alpha receptors d. amphetamine causes mydriasis by inhibiting noradrenaline reuptake

Last Answer : phenylephrine causes mydriasis by stimulating the alpha receptors

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

The following mydriatic does not produce cycloplegia: A. Phenylephrine B. Tropicamide C. Cyclopentolate D. Homatropine

Description : The following mydriatic does not produce cycloplegia: A. Phenylephrine B. Tropicamide C. Cyclopentolate D. Homatropine

Last Answer : A. Phenylephrine

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Description : Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Last Answer : C. Slow intravenous infusion

The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Description : The following type/types of noradrenaline uptake is blocked by reserpine: A. Axonal uptake B. Granular uptake C. Extraneuronal uptake D. All of the above

Last Answer : B. Granular uptake

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Description : Noradrenaline is administered by: A. Subcutaneous injection B. Intramuscular injection C. Slow intravenous infusion D. All of the above routes

Last Answer : C. Slow intravenous infusion

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase